BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary
A big investor (KKR) that owns BridgeBio stock is selling some of their shares to other people. This is a normal way investors sometimes get cash, and it doesn't mean anything is wrong with the company itself.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.